Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939546 · ClinicalTrials.gov registry record · NA
The FOUNDATION Study
A NA study, sponsored by Evolve BioSystems.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03939546 is a NA study that has completed, run by Evolve BioSystems. The registered enrollment target is 30 participants.
The verdict
NCT03939546, a NA study, has completed, sponsored by Evolve BioSystems.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The FOUNDATION study will evaluate the tolerability of feeding preterm infants a B. infantis probiotic (EVC001) as the primary endpoint. This particular strain of Bifidobacterium has been shown to uniquely utilize oligosaccharides found in human breast milk, possibly providing a nutritional benefit for the infant consuming breast milk when B. infantis is colonized in the gut.
Interventions
- OTHER B. infantis EVC001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-07-03 |
| Est. Completion | 2021-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939546
The ClinicalTrials.gov registry entry for NCT03939546 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evolve BioSystems, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which B. infantis EVC001 is the first listed.
NCT03939546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939546 about?
NCT03939546 is a clinical study titled "The FOUNDATION Study". The FOUNDATION study will evaluate the tolerability of feeding preterm infants a B. infantis probiotic (EVC001) as the primary endpoint. This particular strain of Bifidobacterium has been shown to uniquely utilize oligosaccharides found in human breast milk, possibly providing a nutritional benefit ...
What is the current status of trial NCT03939546?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2019-07-03. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT03939546?
The interventions under investigation include: B. infantis EVC001 (OTHER).
Who is sponsoring clinical trial NCT03939546?
This trial is sponsored by Evolve BioSystems, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.